Overview Animation
I. Overview
Our colorectal cancer targeted therapy project drives innovation through a systematic human-centered practice approach. By iterating through five key cyclic phases, we ensure the project remains closely aligned with clinical needs and social value.
In the Insight Capture phase, we gained in-depth understanding of core challenges in colorectal cancer treatment—such as low drug delivery efficiency and severe toxic side effects—through literature research and clinical interviews. These findings charted the course for our technology development. Building on these insights, during the Ethics Anchor phase, we prioritized safety and controllability as core principles in technology design, establishing a comprehensive risk assessment and management mechanism to ensure the project follows a path of responsible innovation.
Through Dialogue Co-creation, we maintained in-depth communication with clinicians, research experts, and patient groups. These dialogues directly led to the formulation of the "oral + microneedle" dual-route delivery strategy and facilitated breakthroughs in key technical areas, including molecular dynamics simulation and engineered bacteria construction. In the Market Insight phase, we systematically analyzed the needs and expectations of various stakeholders to ensure the project plan embodies both scientific innovation and practicality in clinical application and market feasibility.
Finally, by establishing continuous Feedback Cycles, we continuously collect and incorporate suggestions from all parties to drive ongoing project optimization. Every improvement to technical details and every adjustment to the plan embodies the collective wisdom of multiple stakeholders.
We believe this systematic human-centered practice approach not only ensures the scientific rigor of the project but also enables our innovative outcomes to truly serve patient needs, bringing substantial progress to colorectal cancer treatment.
II. Sources of Inspiration
a. Signals of Dilemmas in Literature
Our research began with the identification of severe therapeutic challenges in the field of colorectal cancer (CRC). Global cancer statistics indicate that CRC is the third most common cancer and the second leading cause of cancer-related death worldwide, with its incidence and mortality burden continuing to rise [1]. Despite advancements in treatment methods, the 5-year survival rate for patients with advanced CRC remains discouraging [2].
Existing therapies have significant limitations: Conventional chemotherapy causes severe systemic toxicity [3]; Targeted therapy has restricted efficacy due to tumor heterogeneity and acquired drug resistance [4]; Immune checkpoint inhibitors are only effective for a small subset of patients with specific molecular characteristics (e.g., dMMR/MSIH) [5]. A deeper bottleneck lies in inefficient drug delivery. Studies have shown that the delivery efficiency of most nanomedicines is less than 1% in solid tumors, primarily due to high interstitial pressure and dense stroma [6]. These "signals of dilemmas" revealed in literature clearly highlight the urgency of developing a new generation of highly efficient and precise drug delivery systems.
Figure 1. The Evolution of Colorectal Cancer Therapy
b. Policy Guidance
The establishment and implementation of this project are closely aligned with national and local policy directions and strategic layouts. Focusing on key technical bottlenecks in colorectal cancer treatment, we are committed to developing a non-invasive microneedle delivery system based on ACPP targeting.
This project accurately aligns with the overall requirements for strengthening cancer prevention and treatment outlined in the Healthy China 2030 Plan and the key support directions of Beijing Municipality for the open development of the entire biopharmaceutical industry chain and innovative medical device advancement. It falls under the category of "high-end pharmaceutical formulations" and "intelligent medical devices" explicitly encouraged by policies.
The project addresses critical clinical pain points, including the strong systemic toxicity of traditional chemotherapy drugs, low bioavailability of targeted drugs, and less than 1% tumor accumulation efficiency of existing delivery systems. By optimizing precise molecular recognition and tissue-level delivery routes, we have developed a dual-route delivery scheme combining oral administration and microneedles.
Meanwhile, the project will fully leverage Beijing's resource advantages in concept verification platforms, pilot-scale production platforms, and research ward construction. It will utilize review and approval mechanisms such as "collaborative linkage between R&D and review" and "early intervention" to accelerate technological R&D and achievement transformation.
The implementation of this project will not only enhance China's innovation capabilities in the field of drug delivery systems but also hold significant strategic importance for improving the treatment outcomes of colorectal cancer patients and promoting the high-quality development of the medical and health industry.
c. Perspectives from People Around Us
Who We Connected With
We conducted in-depth clinical interviews and exchanges with Professor Wang Wenquan, Chief Physician of the Department of General Surgery at Zhongshan Hospital. Dr. Wang holds a doctoral degree in Surgery from Fudan University, where he studied under the internationally renowned oncologist, Academician Tang Zhaoyou. After graduation, he worked under the mentorship of Professor Ni Quanxing and Professor Yu Xianjun, leading experts in pancreatic cancer research.
With over 15 years of extensive clinical experience in general surgery, Dr. Wang has profound expertise in surgical treatment and post-operative care for tumors such as pancreatic cancer, and has led a number of national-level scientific research projects. During our exchanges, Dr. Wang provided highly valuable professional insights from the unique perspective of general surgical clinical practice, combined with the actual post-operative treatment experiences of numerous surgical patients.
Why Contact
The primary goal of this clinical exchange was to break free from the limitations of pure laboratory research and gain in-depth understanding of the specific challenges faced in cancer treatment within real healthcare settings. We focused on key dimensions including doctor-patient communication, treatment option selection, and patient experience. Through the clinical perspective of professional physicians, we aimed to systematically identify core issues in the current treatment system that urgently require improvement. Feedback from frontline clinical practice will help align our research with real-world needs and ensure consistency between research directions and clinical practice.
What We Learned
This in-depth exchange yielded several key insights. Dr. Wang clearly noted that significant differences in patients' cultural backgrounds and cognitive levels pose major challenges to doctor-patient communication. Additionally, the "killing a thousand enemies while losing eight hundred" characteristic of existing targeted drugs remains a critical pain point in clinical treatment.
Notably, Dr. Wang emphasized that oral administration is more readily accepted by patients in clinical practice due to its convenience and non-invasiveness—a stark contrast to patients' general resistance to frequent intravenous injections. These profound clinical insights made us realize that modern medical care must not only pursue improved efficacy but also prioritize humanistic care and pain minimization during treatment. Patients' emphasis on treatment experience often exceeds our expectations.
Alignment with Our Project
Based on these valuable clinical insights, we made important adjustments and optimizations to the project direction. We will firmly adhere to the three core principles of "painless, minimally invasive, and convenient" in project design and commit to developing a new transdermal delivery system with practical clinical value.
We deeply recognize that true medical innovation must not only overcome technical bottlenecks but also prioritize the protection of patients' dignity and comfort during treatment. Therefore, throughout the technology development process, we will continuously focus on the core concept of "patient-friendly treatment." Through innovative delivery system design, we will effectively improve patients' treatment experience and quality of life, ensuring that technological progress truly serves patients' practical needs.
d. Stakeholder Analysis
Understanding and addressing the core concerns of various stakeholders is crucial to the success of our project. Stakeholders play a decisive role in determining the project's development direction, achieving implementation outcomes, and realizing social value. Their positions, demands, and potential concerns directly influence the project's progress and final results; thus, systematic and forward-looking communication and collaboration are essential.
Through a Strengths-Weaknesses-Opportunities-Threats (SWOT) analysis of four core stakeholder groups—patients, medical institutions, enterprises, and regulatory authorities—we gained a clearer understanding of each party's position and demands in the project. The analysis revealed significant potential for complementarity and synergy among different stakeholder groups: patients' expectations for precise treatment align with medical institutions' needs for technological innovation, while enterprises' R&D capabilities and regulatory authorities' standardized guidance form a positive checks-and-balances mechanism. This complementary relationship helps balance differences in resources, risks, and benefits among parties, creating a more stable development environment for the project.
Figure 2. Stakeholder Influence Matrix
Based on this analysis, we plan to conduct further targeted stakeholder interviews to gather more in-depth feedback and continuously refine the project plan. By establishing a regular communication mechanism, we aim to fully address the needs of all parties throughout the project lifecycle, integrate scientific value, clinical value, and social value into a cohesive whole, and ensure that the project outcomes truly benefit all stakeholders involved.
III. Ethical and Moral Considerations
Throughout the project lifecycle, we have consistently placed ethical thinking at the core of technological innovation, striving to build a safe, credible, and responsible research framework. We deeply recognize that the sound development of cutting-edge technologies cannot proceed without guidance from ethical standards. To this end, we have engaged in multiple rounds of in-depth dialogues with a diverse group of experts and scholars, systematically embedding Ethical and Moral Considerations into every stage of the project.
Who We Connected With
During the project advancement, we specifically invited experts and scholars from various universities for in-depth exchanges. We extend our sincere gratitude to Professor Zhang Chong from Tsinghua University for his strategic guidance in the early phase of the project, Professor Li Yong from Beijing Institute of Technology for his professional support on technical implementation pathways, and Professor Wang Ran from Hebei Medical University for her valuable insights from a clinical ethics perspective. These interdisciplinary and multi-domain expert inputs have laid a solid theoretical foundation for our project.
Why Contact
We organized these expert dialogues to enhance the project's ethical framework and technical solutions from diverse professional angles. Through guidance from ethics experts, we sought to clarify the ethical boundaries of technology development; leveraging advice from engineering experts, we aimed to optimize technical implementation routes; and drawing on perspectives from clinical ethics experts, we worked to ensure the project design aligns with ethical standards in medical practice. These exchanges helped us establish a more comprehensive and responsible research framework.
Key Takeaways
These in-depth exchanges yielded critical insights across multiple dimensions. Professor Zhang Chong helped us clarify the boundaries and core issues of technological ethics; Professor Li Yong provided key insights into technical implementation pathways, supporting us in translating ethical principles into actionable safety designs. Most notably, Professor Wang Ran offered profound reminders from the perspectives of clinical ethics and patient rights, emphasizing that full respect for patients' right to information and right to autonomous decision-making constitutes the ethical bottom line of medical innovation. These guidelines reinforced our understanding that responsible technological innovation must balance technical feasibility with ethical appropriateness.
Alignment with Our Project
Guided by this professional input, we made significant enhancements to the project. Under Professor Zhang Chong's guidance, we established a clear ethical review mechanism; following Professor Li Yong's recommendations, we translated ethical requirements into specific technical implementation plans; and particularly, with Professor Wang Ran's guidance, we further refined our patient communication and informed consent processes to ensure information is conveyed completely and comprehensibly. These improvements enable our project to not only pursue technological innovation but also commit to building a responsible research system that adheres to ethical norms.
Through these in-depth ethical discussions, we developed an innovative practice of "preventive ethics"—conducting ethical assessments proactively before potential issues arise at every key stage of technology development, rather than making corrections after issues arise. This responsible research approach ensures that while our project pursues scientific breakthroughs, it always maintains deep respect for life and society.
IV. Advancing Project Development Through Collaboration & Dialogue
a. Project Design: Defining Core Direction
Who We Connected With
Figure 3. Professor Zhang Yongqian
Professor Zhang Yongqian, Associate Professor and Doctoral Supervisor at the School of Medical Technology, Beijing Institute of Technology. His research focuses on integrating Biotechnology (BT) and Information Technology (IT) to advance studies in life omics and space pharmaceutical development.
Why Contact
We sought to leverage Professor Zhang's expertise in drug R&D and tumor treatment to systematically identify the key bottlenecks in current colorectal cancer pharmacotherapy—specifically in efficacy, safety, and delivery technology. This input aimed to provide a scientific basis for our oral-microneedle synergistic delivery protocol.
Key Insights Gained
Professor Zhang highlighted that the fundamental challenge in colorectal cancer pharmacotherapy lies in balancing drug efficacy and safety. Traditional chemotherapeutic agents such as 5-FU and oxaliplatin cause severe systemic toxicity, including dose-limiting side effects like leukopenia (due to myelosuppression), mucositis, diarrhea, and neurotoxicity. In targeted therapy, EGFR inhibitors (e.g., cetuximab) are only effective in patients with wild-type KRAS/BRAF, while HER2-targeted drugs benefit merely 3–5% of patients with HER2 amplification—revealing significant biomarker dependence. More critically, monoclonal antibodies, due to their large molecular weight and poor tissue permeability, fail to reach effective concentrations in deep tumor regions, often leading to acquired drug resistance.
Professor Zhang emphasized the pivotal role of drug delivery systems, noting that existing nanomedicines exhibit extremely low penetration efficiency in tumor tissues—with only ~0.7% of the administered dose reaching the tumor site. Additionally, oral administration faces challenges such as degradation in the gastrointestinal environment and obstruction by the mucus barrier, resulting in drug bioavailability generally below 10%.
Alignment with Our Project
Informed by Professor Zhang's insights, we designed a targeted delivery system centered on ACPP (Activated Cell-Penetrating Peptide). The enzyme-responsive nature of this system enables specific activation in the tumor microenvironment, enhancing the drug's ability to target cancer cells at the molecular level while minimizing damage to normal tissues. For delivery methods, we combined oral administration with transdermal microneedles—a dual-path design that respects patient medication preferences while enabling precise drug delivery and release via an intelligent controlled-release system. Professor Zhang affirmed that this protocol fundamentally addresses key issues such as poor drug selectivity, high systemic toxicity, and low delivery efficiency, laying an important foundation for developing a colorectal cancer treatment strategy that is both highly effective and safe.
b. Project Refinement: Finalizing the Project Protocol
Who We Connected With
In the early project phase, we conducted in-depth exchanges with Dr. Wang Wenquan from Zhongshan Hospital, gaining critical insights from clinical practice.
Why Contact
We aimed to understand patients' actual preferences and acceptance of long-term treatment administration methods through dialogues with clinical experts. This ensured our technical route not only aligns with scientific innovation but also meets real-world clinical needs.
Key Insights Gained
During initial technical route planning, we initially prioritized microneedle transdermal delivery as the core approach, focusing on the convenience of long-term treatment. However, in-depth discussions with Dr. Wang Wenquan from Zhongshan Hospital yielded key insights that reshaped our technical strategy. From a clinical perspective, Dr. Wang stated clearly: "Generally, oral administration is more acceptable to patients." This observation highlighted a critical patient preference—oral administration, with its non-invasiveness, convenience, and high autonomy, offers significant compliance advantages in long-term treatment scenarios.
This feedback prompted our team to conduct a systematic reassessment of the original technical plan. We realized that relying solely on microneedle delivery, despite its technical innovation, could pose challenges in patient acceptance—undermining the project's practical application value. Additionally, Dr. Wang's comment that "as long as the treatment is effective for patients, family members generally do not object" further reinforced our core design philosophy: the selection of technical routes must consider not only patient acceptance but also ensure the treatment's clinical efficacy.
Figure 4. Clinical Snapshot: Dialogue with Dr. Wang Wenquan
Alignment with Our Project
Guided by these two key insights, we innovatively proposed a "oral + microneedle" dual-delivery strategy. Oral engineered bacteria capsules serve as the primary route—respecting patients' medication habits and psychological preferences—with a carefully designed enteric coating to ensure precise delivery of active ingredients to intestinal targets. Meanwhile, we retained microneedle transdermal delivery as an auxiliary route, providing targeted supplementation for treatment phases requiring more potent control.
Direct feedback from clinical experts helped us move beyond pure technical optimization, integrating "patient acceptance" as a core criterion in technical route selection. This dual-path design ensures the project aligns with both cutting-edge scientific trends and real-world clinical needs. Both routes share our core ACPP targeting technology, guaranteeing precise tumor targeting and controlled drug release regardless of the delivery method. We are confident that this design—balancing patient acceptance and maximal efficacy—will significantly enhance the project's clinical translation value, ensuring innovative technologies truly serve patient needs.
c. Project Implementation: Overcoming Technical Bottlenecks
Who We Connected With
Professor Wang Qi, Professor and Doctoral Supervisor at Zhejiang University, and current Director of the Institute of Molecular Design and Molecular Thermodynamics at Zhejiang University. His research focuses on molecular simulation and design, molecular thermodynamics, and nanomaterials. He has published over 80 papers in international journals such as Biomaterials and Soft Matter, and leads projects funded by the National Natural Science Foundation of China. His key achievements include research on transport behavior in nano-microporous fluids, molecular sieve separation of alkane mixtures, and nanopore simulation for DNA sequencing.
Why Contact
When using GROMACS to perform molecular dynamics simulations of TRACER-IL24 and MMP9 enzyme, we encountered critical technical bottlenecks: inaccuracies in force field modeling for Zn²⁺ ions in the MMP9 enzyme's active center, and failure to identify the protonation state of Zn²⁺-coordinating atoms.
In initial modeling, we attempted conventional force field parameters but found that the unique atomic types of Zn²⁺ and its coordinating atoms could not be recognized—preventing accurate simulation of their coordination geometry. To address this, we adopted a rigorous approach combining literature review and direct communication. First, we systematically reviewed studies on Zn²⁺ modeling in metalloproteinases, focusing on research by Chen et al. (2021), which provided clear guidelines for force field handling of Zn²⁺ in similar coordination environments. To ensure accuracy and applicability, we proactively contacted Professor Wang Qi (corresponding author of Chen's team) via email, detailing the dual-coordination structure of Zn²⁺ in our MMP9 enzyme and seeking advice on topology construction methods and force field parameter selection for the hexacoordinate catalytic center and tetracoordinated domain.
Key Insights Gained
In his response, Professor Wang Qi clarified that distinct topology construction methods and force field parameters are required for the hexacoordinate catalytic center and tetracoordinated domain of MMP9 enzyme (due to their different coordination modes). He recommended the validated ZAFF force field parameter system and emphasized that coordinating residues should undergo dehydrotreatment to avoid interference from protonation states on charge distribution.
Alignment with Our Project
Following this guidance, we used the correct force field topology file for Zn²⁺ and adjusted coordination bond lengths and angles to ensure the force field accurately reflects Zn²⁺'s polarization effects and charge transfer properties.
This solution yielded significant progress: the reconstructed MMP9 enzyme-Zn²⁺ system successfully identified and reproduced the octahedral structure of the hexacoordinate catalytic center and the tetrahedral configuration of the tetracoordinated domain. In subsequent molecular dynamics simulations, the TRACER-IL24/MMP9 enzyme complex exhibited significantly improved structural stability (with a stable RMSD curve), and atomic-level interaction analysis yielded reliable results. These steps not only resolved the core technical issue in modeling but also ensured the scientific rigor of the entire research system—laying a solid foundation for subsequent binding free energy calculations and mechanism-of-action analysis.
Figure 5. Dialogue with Professor Wang Qi and Robert Vacha
d. Project Implementation: Integrating Engineering & Clinical Thinking
Who We Connected With
Figure 6. Professor Lü Xuefei
Professor Lü Xuefei, Associate Professor and Vice Dean of the School of Life Sciences, Beijing Institute of Technology. Her research focuses on developing novel protein separation and analysis technologies to address technical needs in proteomics, clinical diagnostics, and space life sciences.
Why Contact
During multiple rounds of construct validation and protein expression experiments, we faced a persistent technical bottleneck: while we successfully obtained recombinant plasmids and engineered bacteria strains, we could not achieve sufficient target protein concentration during purification. We initially hypothesized low recombinant plasmid expression was the cause, so we attempted to boost expression by increasing IPTG induction concentration and tested three concentration methods (water bath, ammonium sulfate precipitation, and lyophilization) to enhance final protein solution concentration. However, rigorous experimental validation showed no significant improvement in protein concentration—indicating the root cause remained unaddressed.
As we explored solutions, our modeling team proposed a new hypothesis via computational simulation: the TRACER protein may have low solubility (due to its unique physicochemical properties) and tend to accumulate in the precipitate fraction after ultrasonic lysis. We immediately adjusted our protocol to extract target protein from both supernatant and precipitate fractions post-ultrasonication. Regrettably, no high-concentration target protein was detected in either fraction—suggesting the issue extended beyond protein solubility.
Key Insights Gained
Faced with this ongoing challenge, we sought guidance from Professor Lü Xuefei. After in-depth analysis of our experimental data and procedures, she recommended fundamental optimization of genetic circuit design and proposed an innovative technical pathway: modifying the existing genetic circuit to transform Escherichia coli from a mere in vitro drug production "factory" into an intelligent delivery carrier capable of directly entering the human body to exert therapeutic effects.
Alignment with Our Project
Inspired by this innovative concept, we redesigned the genetic circuit: under normal conditions, the Pj23100 promoter drives basal expression of the TRACER protein; when the engineered bacteria reach the specific microenvironment of colorectal cancer tissue, a built-in lysis mechanism is specifically activated to release the accumulated TRACER protein for treatment. This dual-protection mechanism not only resolves the issue of insufficient in vitro expression but also establishes an intelligent in vivo delivery system that enables continuous drug production and precise release—providing a more reliable technical foundation for ensuring therapeutic efficacy.
e. Dialogue and Co-creation: Insights from the iGEM Community
Who We Connected With
Throughout the project R&D process, we actively built a cross-regional, cross-educational-stage iGEM collaboration network, establishing in-depth partnerships with 8 outstanding teams worldwide. This network includes 2 high school teams (SubCat Team, Profuture Team) and 6 university teams (iGEM teams from Tsinghua University, Peking University, Yan'an University, Jilin University, and two teams from Beijing Institute of Technology: BIT-China and BIT-LLM). We ensured sustained, in-depth knowledge sharing and experience exchange through regular joint seminars and an online collaboration platform.
Why Contact
We aimed to build an open, collaborative research ecosystem, leveraging the unique strengths of teams with diverse educational and professional backgrounds to achieve breakthroughs in key areas: engineered bacteria strain construction, drug delivery system design, and biosafety assurance. Specifically, we sought innovative solutions to core technical challenges (e.g., protein expression optimization, genetic circuit stability enhancement, drug controlled-release mechanisms) through cross-team brainstorming, while developing a more comprehensive biosafety risk assessment system.
Key Insights Gained
These sustained, in-depth collaborations yielded valuable technical insights and practical experience. In engineered bacteria strain construction, teams shared diverse promoter optimization strategies and protein expression protocols; in drug delivery system design, we conducted in-depth discussions on the pros and cons of various targeted delivery mechanisms and controlled-release technologies; in biosafety, teams' safety control protocols provided critical references. Notably, exchanges with high school teams often brought unexpected innovative perspectives, while university teams offered more systematic engineering solutions. These diverse viewpoints helped us break free from conventional thinking and identify new breakthrough directions for multiple technical challenges.
Alignment with Our Project
Drawing on these valuable collaborative insights, we comprehensively optimized and upgraded the project. Technically, we adopted recommendations from multiple teams to improve the genetic circuit design of engineered bacteria—significantly enhancing protein expression efficiency and system stability. For the delivery system, we integrated teams' controlled-release protocols to develop a more precise drug release mechanism. In biosafety, we incorporated multi-party experience to establish a multi-layered safety control system.
Additionally, this in-depth collaboration model led us to develop a standardized problem-solving framework, enabling the team to more effectively integrate diverse perspectives and address R&D challenges. These improvements not only elevated the project's technical standards but also laid a stronger foundation for subsequent clinical applications.
Figure 7. Cross-team Brainstorm with iGEMers
This open, inclusive collaborative environment has kept the team innovative and adaptable when facing technical challenges. This comprehensive collaboration mechanism embodies the core value of collaborative innovation in modern research. By building an open, shared innovation network, we have not only accelerated technical breakthroughs but also explored an efficient collaborative R&D pathway. The synergistic effects of this model continue to inject innovation momentum into the project and lay a solid foundation for addressing more complex biomedical challenges.
V. Feedback Cycles: Establishing a Project Iteration Mechanism for Continuous Optimization
To ensure ongoing optimization of the project's scientific rigor and practical applicability, we have established a systematic, institutionalized feedback cycle mechanism. This mechanism aligns project R&D with clinical needs and technical frontiers through the seamless integration of four key links with organic connection.
In feedback channel development, we built a multi-dimensional information collection network. Beyond regular expert review meetings and clinical physician interviews, we established a dedicated patient feedback channel to gain in-depth insights into practical pain points during treatment. Additionally, a peer review mechanism with research institutions provides interdisciplinary professional perspectives. These diverse channels ensure the project promptly captures the core needs of all stakeholders.
In the evaluation and response phase, we implemented a dual-track meeting system: monthly project evaluation meetings address immediate technical feedback to quickly adjust experimental protocols; quarterly expert advisory meetings review the project's overall direction from a macro perspective, ensuring the R&D pathway remains scientifically sound and feasible. This combination of short-term and long-term oversight enables the project to resolve specific issues promptly while maintaining strategic alignment.
To enhance decision-making rigor, we appointed dedicated feedback managers to organize and analyze data. All collected suggestions undergo classification, prioritization, and feasibility assessment to form structured data records. Through trend analysis and correlation studies of feedback data, we accurately identify the most critical issues requiring resolution—maximizing the impact of limited R&D resources.
Most importantly, we fostered a culture of continuous improvement within the team. By establishing an "Innovation Suggestion Award" and hosting regular improvement workshops, we encourage every team member to proactively identify issues and propose optimization ideas. This bottom-up improvement mechanism complements the institutionalized feedback system, embedding continuous optimization into the team's DNA.
Figure 8. Feedback Integration System
The establishment and operation of this feedback mechanism have not only significantly improved R&D efficiency but also cultivated the team's systems thinking and adaptability when facing complex research challenges. By effectively translating external feedback into internal improvement momentum, we ensure the project undergoes continuous refinement at every R&D stage—laying a solid foundation for ultimately achieving our project goals.
References:
- [1]. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
- [2]. Biller L H, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review[J]. JAMA, 2021, 325(7): 669-685.
- [3]. Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer[J]. Critical Reviews in Oncology/Hematology, 2015, 94(3): 339-348.
- [4]. Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer[J]. Nature, 2012, 486(7404): 532-536.
- [5]. Le D T, Durham J N, Smith K N, et al. Mismatch repair deficiency predicts response of solid tumors to PD1 blockade[J]. Science, 2017, 357(6349): 409-413.
- [6]. Wilhelm S, Tavares A J, Dai Q, et al. Analysis of nanoparticle delivery to tumours[J]. Nature Reviews Materials, 2016, 1(5): 112.
- [7]. Zhou X H, Luo Z, Tian H, et al. De-shielding of activatable cell-penetrating peptides: recognizing and releasing in activation process [J]. Research on Chemical Intermediates, 2021, 47(1): 19-38.